EQS-News: Gerresheimer AG
/ Key word(s): Miscellaneous/Sustainability
Gerresheimer Successfully Completes Investment in State-of-the-Art Glass Production Facility in Lohr
Duesseldorf/Lohr, May 12, 2025. Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and cosmetics industries, has successfully completed an expansion and modernization project at its Lohr site with a total investment volume of around EUR 100 million after more than two years of planning and construction. “Our investments in cutting-edge production technology, such as the new facility in Lohr, secure the future,” explains Dietmar Siemssen, CEO of Gerresheimer AG. “With state-of-the-art facilities for high-value products, we are strengthening our competitiveness, securing long-term jobs in the region and making significant progress toward our ambitious sustainability goals.” New oxy-hybrid furnace for enhanced efficiency and sustainability Industrial glass production furnaces are usually replaced every 8 to 12 years. Gerresheimer has used the planned replacement of the white glass furnace in Lohr to upgrade to the latest technology and expand production capacity to support its planned growth. The new furnace can operate with up to 50% electricity. This diversifies the energy supply and reduces CO2e emissions by up to 40% compared to conventional furnace technology. Currently, the Lohr site sources approximately 70% of its electricity from renewable energy, with plans to increase this share to 100% by 2030. Modernization also includes an upgrade to the cooling system: the new adiabatic cooling technology is more energy-efficient and consumes less water than conventional cooling systems, further supporting the company’s sustainability goals. The project was meticulously planned and executed by Gerresheimer experts over more than two years and implemented during ongoing operations. Amber glass production continued without interruption at the site. To meet increased electricity demand, new power lines were installed and new supply buildings constructed. The expansion also involved a new cooling system and the expansion of production halls. The actual furnace replacement, including the dismantling of the old furnace and construction of the new oxy-hybrid furnace, took place from January 2025 and was completed within four months. Several production lines were also upgraded to the latest generation and equipped with Gerresheimer’s AI-based inspection system for quality assurance. This technology will enable the Lohr plant to further increase its share of high-value products in the future. Investment supporting further growth At the Moulded Glass plant in Lohr, Gerresheimer produces a wide range of glass products made of white and amber glass with around 500 employees from syrup, dropper, tablet and infusion bottles for the pharmaceutical industry to glass containers and bottles for the food and beverage industry. The plant in Lohr is one of three Moulded Glass plants in Germany and one of eight Moulded Glass plants worldwide within the Gerresheimer Group. The modernization and expansion project at the Lohr site is one of the company's key investment projects in recent years for the further profitable growth of the Group.
Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of drug containment solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, cartridges, ampoules, tablet containers, infusion, dropper and syrup bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With over 40 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. Together with Bormioli Pharma, the Group generated revenues of around EUR 2.4bn in 2024 and currently employs around 13,400 people. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).
12.05.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. |
Language: | English |
Company: | Gerresheimer AG |
Klaus-Bungert-Str. 4 | |
40468 Duesseldorf | |
Germany | |
Phone: | +49-(0)211/61 81-00 |
Fax: | +49-(0)211/61 81-121 |
E-mail: | gerresheimer.ir@gerresheimer.com |
Internet: | http://www.gerresheimer.com |
ISIN: | DE000A0LD6E6 |
WKN: | A0LD6E |
Indices: | MDAX (Aktie) |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 2135510 |
End of News | EQS News Service |
|
2135510 12.05.2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.